Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opus Genetics (IRD) Total Current Liabilities (2019 - 2026)

Opus Genetics has reported Total Current Liabilities over the past 8 years, most recently at $9.3 million for Q1 2026.

  • Quarterly Total Current Liabilities fell 61.49% to $9.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $9.3 million through Mar 2026, down 61.49% year-over-year, with the annual reading at $7.8 million for FY2025, 31.11% down from the prior year.
  • Total Current Liabilities was $9.3 million for Q1 2026 at Opus Genetics, up from $7.8 million in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $29.1 million in Q3 2025 and troughed at $2.7 million in Q3 2022.
  • The 5-year median for Total Current Liabilities is $5.8 million (2023), against an average of $8.7 million.
  • Year-over-year, Total Current Liabilities surged 380.99% in 2025 and then tumbled 61.49% in 2026.
  • A 5-year view of Total Current Liabilities shows it stood at $2.8 million in 2022, then surged by 46.82% to $4.0 million in 2023, then surged by 179.44% to $11.3 million in 2024, then crashed by 31.11% to $7.8 million in 2025, then rose by 20.04% to $9.3 million in 2026.
  • Per Business Quant, the three most recent readings for IRD's Total Current Liabilities are $9.3 million (Q1 2026), $7.8 million (Q4 2025), and $29.1 million (Q3 2025).